Search Result

Results for "

N-methyl-d-aspartate (NMDA)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (1) Adrenergic Receptor (1) Apoptosis (2) Cholinesterase (ChE) (2) Cytochrome P450 (1) Drug Metabolite (4) Endogenous Metabolite (11) GABA Receptor (1) GlyT (4) Histamine Receptor (1) iGluR (62) Isotope-Labeled Compounds (3) LXR (1) mAChR (7) MMP (1) nAChR (1) Neuropeptide Y Receptor (1) Opioid Receptor (4) PARP (1) Potassium Channel (1) Prostaglandin Receptor (1) Serotonin Transporter (1) Virus Protease (4)
By Research Areas:	Cancer (5) Cardiovascular Disease (1) Endocrinology (1) Infection (4) Inflammation/Immunology (8) Metabolic Disease (2) Neurological Disease (61)

By Targets:

17β-HSD (1)

Adrenergic Receptor (1)

Apoptosis (2)

Cholinesterase (ChE) (2)

Cytochrome P450 (1)

Drug Metabolite (4)

Endogenous Metabolite (11)

GABA Receptor (1)

GlyT (4)

Histamine Receptor (1)

iGluR (62)

Isotope-Labeled Compounds (3)

LXR (1)

mAChR (7)

MMP (1)

nAChR (1)

Neuropeptide Y Receptor (1)

Opioid Receptor (4)

PARP (1)

Potassium Channel (1)

Prostaglandin Receptor (1)

Serotonin Transporter (1)

Virus Protease (4)

By Research Areas:

Cancer (5)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (4)

Inflammation/Immunology (8)

Metabolic Disease (2)

Neurological Disease (61)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100807

Quinolinic acid 4 Publications Verification	Endogenous Metabolite iGluR	Neurological Disease Inflammation/Immunology
Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .

HY-100807S

Quinolinic acid-d3	Endogenous Metabolite iGluR	Neurological Disease Inflammation/Immunology
Quinolinic acid-d₃ is the deuterium labeled Quinolinic acid. Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction[1][2].

HY-W001601

Budipine	iGluR	Neurological Disease
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease .

HY-100807R

Quinolinic acid (Standard) 4 Publications Verification	Endogenous Metabolite iGluR	Neurological Disease Inflammation/Immunology
Quinolinic acid (Standard) is the analytical standard of Quinolinic acid. This product is intended for research and analytical applications. Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .

HY-N2311

Ibotenic acid 5+ Cited Publications (RS)-Ibotenic acid; DL-Ibotenic acid	iGluR	Neurological Disease
Ibotenic acid has agonist activity at both the N-methyl-D-aspartate (NMDA) and trans-ACPD or metabolotropic quisqualate (Q_m) receptor sites.

HY-P1287

Conantokin-T	iGluR	Neurological Disease
Conantokin-T is a γ-carboxyglutamate-containing, N-methyl-D-aspartate (NMDA) antagonist peptidewith an IC₅₀ value of 2 μM. Conantokin-T inhibits NMDA receptor-mediated calcium influx in central nervous system neurons. Conantokin-T can be purified from the venom of the fish-hunting cone snail, Conus tulipa .

HY-123655

Fenazinel dihydrochloride	Others	Neurological Disease
Fenazinel dihydrochloride, an N-methyl-D-aspartate (NMDA) receptor antagonist, shows promise as a potential treatment for ischemic stroke.

HY-15410

Gacyclidine	iGluR	Others
Gacyclidine, a non competitive **N-methyl-D-aspartate (NMDA)** antagonist, can be used in the study of spinal cord injuries .

HY-15410A

Gacyclidine hydrochloride	iGluR	Others
Gacyclidine hydrochloride, a non competitive **N-methyl-D-aspartate (NMDA)** antagonist, can be used in the study of spinal cord injuries .

HY-W001601A

Budipine hydrochloride	iGluR	Neurological Disease
Budipine hydrochloride is an anti-parkinson agent. Budipine hydrochloride also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine hydrochloride also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine hydrochloride can be used for the research of CNS disorders include Parkinson disease .

HY-101353

LY 235959 (-)-LY 235959	iGluR	Neurological Disease
LY 235959 is a competitive N-methyl-D-aspartate (NMDA)-receptor antagonist. LY 235959 potentiates the anticonvulsant action of antiepileptics .

HY-100807S1

Quinolinic acid-13C7	Isotope-Labeled Compounds	Others
Quinolinic acid- ¹³C₇is the ¹³C labeledQuinolinic acid(HY-100807) . Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .

HY-B0184A

Felbamate hydrate W-554 hydrate; ADD-03055 hydrate	iGluR	Neurological Disease
Felbamate hydrate (W-554 hydrate) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .

HY-B0184

Felbamate 1 Publications Verification W-554; ADD-03055	iGluR	Neurological Disease
Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).

HY-W001601R

Budipine (Standard)	iGluR	Neurological Disease
Budipine (Standard) is the analytical standard of Budipine. This product is intended for research and analytical applications. Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease .

HY-N2370

24-Hydroxycholesterol 1 Publications Verification	iGluR LXR	Neurological Disease
24-Hydroxycholesterol is a natural sterol, which serves as a positive allosteric modulator of N-Methyl-d-Aspartate (NMDA) receptorsR, and a potent activator of the transcription factors LXR.

HY-109164

Zelquistinel AGN-241751; GATE-251	iGluR	Neurological Disease
Zelquistinel (AGN-241751) is a N-methyl-D-aspartate (NMDA) receptor partial agonist used for the research of depression, anxiety and other related psychiatric disorders .

HY-107702

CGP 37849	iGluR	Neurological Disease
CGP 37849 is a potent, competitive and orally active **N-methyl-D-aspartate (NMDA)** receptor antagonist. CGP 37849 is an anticonvulsant in rodents and has antidepressant and anxiolytic-like effects .

HY-114550

LY339434	iGluR	Neurological Disease
LY339434 is a potent and selective agonist for the hydrochloride receptor GluR5. LY339434 affects the rapid death of neurons through n-methyl-D-aspartate (NMDA) receptors .

HY-B0184S1

Felbamate-d5 Felbamyl-d₅; Felbatol-d₅; Taloxa-d₅	iGluR	Neurological Disease
Felbamate-d₅ is the deuterium labeled Felbamate[1]. Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA)[2][3].

HY-138973

Neramexane	iGluR
Neramexane is an oral N-methyl-D-aspartate (NMDA) receptor antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain.

HY-W835175

Neramexane hydrochloride	iGluR
Neramexane hydrochloride is an oral N-methyl-D-aspartate (NMDA) receptor antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain.

HY-15084A

(-)-Dizocilpine maleate (-)-MK-801 maleate	iGluR	Neurological Disease
(-)-Dizocilpine maleate ((-)-MK-801 maleate) is a less active (-)-enantiomer of Dizocilpine. (-)-Dizocilpine maleate is a selective and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with a K_i of 211.7 nM. (-)-Dizocilpine maleate has antidepressant effects .

HY-106441A

Rislenemdaz MK-0657; CERC-301	iGluR	Neurological Disease
Rislenemdaz (CERC-301) is an orally bioavailable and selective N-methyl-D-aspartate (NMDA) receptor subunit 2B (GluN2B) antagonist with K_i and IC₅₀ of 8.1 nM and 3.6 nM, respectively.

HY-45609

L-Cysteine S-sulfate sodium hydrate	iGluR Endogenous Metabolite	Neurological Disease
L-Cysteine S-sulfate sodium hydrate is a potent N-methyl-d-aspartate (NMDA) glutamatergic receptors agonist. L-Cysteine S-sulfate sodium hydrate is the substrate for cystine lyase, it can be used in mass spectrometry operations .

HY-106408A

Nelonemdaz potassium Salfaprodil; Neu2000 potassium	iGluR	Neurological Disease
Nelonemdaz (Salfaprodil) potassium is an NR2B-selective and uncompetitive antagonist of **N-methyl-D-aspartate (NMDA)*. Nelonemdaz potassium is also a free radical scavenger. Nelonemdaz potassium has excellent neuroprotection against NMDA*- and free radical-induced cell death .

HY-100807S2

Quinolinic acid-13C4,15N	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Quinolinic acid-13C4, 15N is an isotopic labeled Quinolinic acid (HY-100807). Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist and has the potential of mediating NMDA neuronal damage and dysfunction .

HY-P1293

Conantokin G	iGluR	Neurological Disease
Conantokin G, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of N-methyl-D-aspartate (NMDA) receptors. Conantokin G inhibits NMDA-evoked currents in murine cortical neurons with an IC₅₀ of 480 nM. Conantokin G has neuroprotective properties .

HY-113084

L-Cysteine S-sulfate	iGluR Endogenous Metabolite	Neurological Disease
L-Cysteine S-sulfate is a potent N-methyl-d-aspartate (NMDA) glutamatergic receptor agonist. L-Cysteine S-sulfate is the substrate for cystine lyase, and can be used in mass spectrometry operations .

HY-100787

L-Cysteine S-sulfate sodium	iGluR Endogenous Metabolite	Neurological Disease
L-Cysteine S-sulfate sodium is a potent N-methyl-d-aspartate (NMDA) glutamatergic receptors agonist. L-Cysteine S-sulfate sodium hydrate is the substrate for cystine lyase, it can be used in mass spectrometry operations .

HY-B0184R

Felbamate (Standard) W-554 (Standard); ADD-03055 (Standard)	iGluR	Neurological Disease
Felbamate (Standard) is the analytical standard of Felbamate. This product is intended for research and analytical applications. Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).

HY-138973A

Neramexane mesylate	iGluR nAChR	Neurological Disease
Neramexane mesylate is an α9α10 cholinergic nicotinic receptors and **N-methyl-D-aspartate receptors*(NMDA*) antagonist. Neramexane mesylate can improve moderate to severe tinnitus, and also shows neuroprotective effects .

HY-106408

Nelonemdaz Salfaprodil free base; Neu2000	iGluR	Neurological Disease
Nelonemdaz (Salfaprodil free base) is an NR2B-selective and uncompetitive antagonist of **N-methyl-D-aspartate (NMDA)*. Nelonemdaz is also a free radical scavenger. Nelonemdaz has excellent neuroprotection against NMDA*- and free radical-induced cell death .

HY-129692

Withanone 1 Publications Verification	iGluR	Neurological Disease
Withanone is an active constituent from Withania somnifera roots with multifunctional neuroprotective effect in alleviating cognitive dysfunction. Withanone affords protection against **N-methyl-D-aspartate (NMDA)**-induced excitotoxicity in Neuron-like cells .

HY-107694

(Rac)-Dizocilpine (Rac)-MK-801	Others	Others
(Rac)-Dizocilpine ((Rac)-MK-801) is the racemate of Dizocilpine (HY-15084B). Dizocilpine (MK-801), a potent anticonvulsant, is a selective and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist .

HY-114869

DPQ 1 Publications Verification	PARP	Neurological Disease
DPQ is a potent PARP-1 inhibitor. DPQ can reduce the N-methyl-d-aspartate (NMDA)-induced PARP activation, restoring ATP to near control levels and significantly attenuating neuronal injury in the severe NMDA exposure model. DPQ can be used for researching neuroprotection .

HY-101037

Sarcosine 1 Publications Verification N-methylglycine; Sarcosin	Endogenous Metabolite GlyT	Cancer
Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .

HY-101178

L-689560	iGluR	Neurological Disease
L-689560 is a potent **N-methyl-D-aspartate (NMDA)** receptor antagonist at the GluN1 glycine binding site. L-689560 is widely used as a radiolabeled ligand in binding studies and used for study the roles of NMDA receptors in normal neurological processes as well as in diseases .

HY-P1293A

Conantokin G TFA	iGluR	Neurological Disease
Conantokin G TFA, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of N-methyl-D-aspartate (NMDA) receptors. Conantokin G TFA inhibits NMDA-evoked currents in murine cortical neurons with an IC₅₀ of 480 nM. Conantokin G TFA has neuroprotective properties .

HY-B1487

Procyclidine hydrochloride Tricyclamol hydrochloride; (±)-Procyclidine hydrochloride	iGluR mAChR	Neurological Disease
Procyclidine (Tricyclamol, (±)-Procyclidine) hydrochloride , an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine hydrochloride can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy .

HY-B0184S

Felbamate-d4	iGluR	Neurological Disease
Felbamate-d₄ (W-554-d4) is the deuterium labeled Felbamate. Felbamate (W-554) is a potent anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).

HY-B1487A

Procyclidine Tricyclamol; (±)-Procyclidine	mAChR iGluR	Neurological Disease
Procyclidine (Tricyclamol; (±)-Procyclidine), an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy .

HY-15086

Selfotel CGS 19755	iGluR	Neurological Disease
Selfotel (CGS 19755) is a selective and competitive antagonist at N-methyl-D-aspartate *(NMDA)*-preferring receptor. CGS 19755 inhibits the binding of [3H]-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid to NMDA-type receptors with an IC₅₀ of 50 nM .

HY-139048

Fluoroethylnormemantine	iGluR	Neurological Disease
Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ ¹⁸F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .

HY-139048A

Fluoroethylnormemantine hydrochloride	iGluR	Neurological Disease
Fluoroethylnormemantine hydrochloride, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ ¹⁸F]-Fluoroethylnormemantine hydrochloride can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine hydrochloride exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .

HY-107703

CGP 39551	iGluR	Neurological Disease
CGP 39551 is a potent, orally active, competitive N-methyl-D-aspartate (NMDA) receptor antagonist with potent anticonvulsant activity . CGP 39551 shows measurable inhibitory activity at both L-[ ³H]-glutamate (K_i=8.4 μM) .

HY-156634

Risevistinel NYX-783	iGluR	Neurological Disease
Risevistinel (NYX-783) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease .

HY-101229

(2R,3S)-Chlorpheg	iGluR	Neurological Disease
(2R,3R)-Chlorpheg is a week antagonist of L-homocysteic acid (L-HCA) induced depolarization.(2R,3R)-Chlorpheg also is a weak **N-methyl-D-aspartate (NMDA)** antagonist .

HY-109097

Otaplimastat SP-8203	MMP iGluR	Neurological Disease
Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury .

HY-100714

DL-AP5 Maximum Cited Publications 17 Publications Verification 2-APV; DL-2-Amino-5-phosphonovaleric acid	iGluR	Neurological Disease Inflammation/Immunology
DL-AP5 (2-APV) is a competitive *NMDA* (N-methyl-D-aspartate) receptor antagonist. DL-AP5 shows significantly antinociceptive activity. DL-AP5 specifically blocks on channels in the rabbit retina .

Cat. No.	Product Name	Target	Research Area

HY-117483

Gly-Pro-Glu	Peptides	Neurological Disease
Gly-Pro-Glu is a neuroactive peptide with a potent action on acetylcholine release. Gly-Pro-Glu is the N-terminal tripeptide of insulin-like growth factor-I. Gly-Pro-Glu inhibits glutamate binds to N-methyl-D-aspartate (NMDA) receptor with an IC₅₀ value of 14.7 μM. Gly-Pro-Glu can be used for the research of neuroprotection .

HY-P1287

Conantokin-T	iGluR	Neurological Disease
Conantokin-T is a γ-carboxyglutamate-containing, N-methyl-D-aspartate (NMDA) antagonist peptidewith an IC₅₀ value of 2 μM. Conantokin-T inhibits NMDA receptor-mediated calcium influx in central nervous system neurons. Conantokin-T can be purified from the venom of the fish-hunting cone snail, Conus tulipa .

HY-P1293

Conantokin G	iGluR	Neurological Disease
Conantokin G, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of N-methyl-D-aspartate (NMDA) receptors. Conantokin G inhibits NMDA-evoked currents in murine cortical neurons with an IC₅₀ of 480 nM. Conantokin G has neuroprotective properties .

HY-113084

L-Cysteine S-sulfate	iGluR Endogenous Metabolite	Neurological Disease
L-Cysteine S-sulfate is a potent N-methyl-d-aspartate (NMDA) glutamatergic receptor agonist. L-Cysteine S-sulfate is the substrate for cystine lyase, and can be used in mass spectrometry operations .

HY-P1293A

Conantokin G TFA	iGluR	Neurological Disease
Conantokin G TFA, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of N-methyl-D-aspartate (NMDA) receptors. Conantokin G TFA inhibits NMDA-evoked currents in murine cortical neurons with an IC₅₀ of 480 nM. Conantokin G TFA has neuroprotective properties .

HY-P3679

Neuropeptide Y (1-24) (human)	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide Y (1-24) (human) is a neuropeptide with potencies in inhibiting the electricity stimulated twitch response of rat vas deferens. Neuropeptide Y (1-24) (human) stimulates N-methyl-D-aspartate (NMDA)-induced neuronal activation in the rat CA3 region of the dorsal hippocampus in vivo .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-100807

Quinolinic acid 4 Publications Verification	Alkaloids Structural Classification Microorganisms Disease markers Pyridine Alkaloids Nervous System Disorder Endogenous metabolite	Endogenous Metabolite iGluR
Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .

HY-100807R

Quinolinic acid (Standard) 4 Publications Verification	Structural Classification Alkaloids Microorganisms Ketones, Aldehydes, Acids Source classification Disease markers Pyridine Alkaloids Nervous System Disorder Endogenous metabolite	Endogenous Metabolite iGluR
Quinolinic acid (Standard) is the analytical standard of Quinolinic acid. This product is intended for research and analytical applications. Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .

HY-N2311

Ibotenic acid Maximum Cited Publications 7 Publications Verification (RS)-Ibotenic acid; DL-Ibotenic acid	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification	iGluR
Ibotenic acid has agonist activity at both the N-methyl-D-aspartate (NMDA) and trans-ACPD or metabolotropic quisqualate (Q_m) receptor sites.

HY-N2370

24-Hydroxycholesterol 1 Publications Verification	Structural Classification Animals Source classification Steroids	iGluR LXR
24-Hydroxycholesterol is a natural sterol, which serves as a positive allosteric modulator of N-Methyl-d-Aspartate (NMDA) receptorsR, and a potent activator of the transcription factors LXR.

HY-45609

L-Cysteine S-sulfate sodium hydrate	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	iGluR Endogenous Metabolite
L-Cysteine S-sulfate sodium hydrate is a potent N-methyl-d-aspartate (NMDA) glutamatergic receptors agonist. L-Cysteine S-sulfate sodium hydrate is the substrate for cystine lyase, it can be used in mass spectrometry operations .

HY-129692

Withanone 1 Publications Verification	Structural Classification Source classification Withania somnifera Plants Solanaceae Steroids	iGluR
Withanone is an active constituent from Withania somnifera roots with multifunctional neuroprotective effect in alleviating cognitive dysfunction. Withanone affords protection against **N-methyl-D-aspartate (NMDA)**-induced excitotoxicity in Neuron-like cells .

HY-101037

Sarcosine 1 Publications Verification N-methylglycine; Sarcosin	Structural Classification Human Gut Microbiota Metabolites Immune System Disorder Microorganisms Classification of Application Fields Source classification Disease markers Endocrine diseases Amino acids Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite GlyT
Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .

HY-P1293

Conantokin G	Structural Classification Natural Products Animals Source classification	iGluR
Conantokin G, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of N-methyl-D-aspartate (NMDA) receptors. Conantokin G inhibits NMDA-evoked currents in murine cortical neurons with an IC₅₀ of 480 nM. Conantokin G has neuroprotective properties .

HY-113084

L-Cysteine S-sulfate	Structural Classification Natural Products Immune System Disorder Neurological Disease Classification of Application Fields Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite Disease Research Fields	iGluR Endogenous Metabolite
L-Cysteine S-sulfate is a potent N-methyl-d-aspartate (NMDA) glutamatergic receptor agonist. L-Cysteine S-sulfate is the substrate for cystine lyase, and can be used in mass spectrometry operations .

HY-100787

L-Cysteine S-sulfate sodium	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	iGluR Endogenous Metabolite
L-Cysteine S-sulfate sodium is a potent N-methyl-d-aspartate (NMDA) glutamatergic receptors agonist. L-Cysteine S-sulfate sodium hydrate is the substrate for cystine lyase, it can be used in mass spectrometry operations .

HY-P1293A

Conantokin G TFA	Natural Products Animals Source classification	iGluR
Conantokin G TFA, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of N-methyl-D-aspartate (NMDA) receptors. Conantokin G TFA inhibits NMDA-evoked currents in murine cortical neurons with an IC₅₀ of 480 nM. Conantokin G TFA has neuroprotective properties .

HY-101037R

Sarcosine (Standard)	Structural Classification Human Gut Microbiota Metabolites Immune System Disorder Microorganisms Source classification Disease markers Endocrine diseases Amino acids Endogenous metabolite	Endogenous Metabolite GlyT
Sarcosine (Standard) is the analytical standard of Sarcosine. This product is intended for research and analytical applications. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .

HY-129692R

Withanone (Standard)	Structural Classification Source classification Withania somnifera Solanaceae Plants Steroids	iGluR
Withanone (Standard) is the analytical standard of Withanone. This product is intended for research and analytical applications. Withanone is an active constituent from Withania somnifera roots with multifunctional neuroprotective effect in alleviating cognitive dysfunction. Withanone affords protection against N-methyl-D-aspartate (NMDA)-induced excitotoxicity in Neuron-like cells .

HY-17387

(-)-Huperzine A 4 Publications Verification Huperzine A	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Anti-aging Terpenoids Huperziaceae Sesquiterpenes Pyridine Alkaloids Huperzia serrata Plants Disease Research Fields	Cholinesterase (ChE) Apoptosis iGluR
(-)-Huperzine A (Huperzine A) is an alkaloid isolated from Huperzia serrata, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC₅₀ of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease .

Cat. No.	Product Name	Chemical Structure

HY-100807S

Quinolinic acid-d3
Quinolinic acid-d₃ is the deuterium labeled Quinolinic acid. Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction[1][2].

HY-B0184S

Felbamate-d4
Felbamate-d₄ (W-554-d4) is the deuterium labeled Felbamate. Felbamate (W-554) is a potent anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).

HY-101037S1

Sarcosine-d3

Sarcosine-d₃ is the deuterium labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].

HY-101037S

Sarcosine-15N

Sarcosine- ¹⁵N is the ¹⁵N-labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].

HY-G0021S1

N-Desmethylclozapine-d8 hydrochloride

N-Desmethylclozapine-d₈ (hydrochloride) is the deuterium labeled N-Desmethylclozapine hydrochloride. N-Desmethylclozapine hydrochloride is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine hydrochloride is a potent, allosteric and partial M1 receptors agonist (EC50=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine hydrochloride is also a δ-opioid agonist[1][2][3].

HY-100807S1

Quinolinic acid-13C7
Quinolinic acid- ¹³C₇is the ¹³C labeledQuinolinic acid(HY-100807) . Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .

HY-B0184S1

Felbamate-d5
Felbamate-d₅ is the deuterium labeled Felbamate[1]. Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA)[2][3].

HY-100807S2

Quinolinic acid-13C4,15N
Quinolinic acid-13C4, 15N is an isotopic labeled Quinolinic acid (HY-100807). Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist and has the potential of mediating NMDA neuronal damage and dysfunction .

HY-G0021S

N-Desmethylclozapine-d8

N-Desmethylclozapine-d₈ is the deuterium labeled N-Desmethylclozapine. N-Desmethylclozapine is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine is a potent, allosteric and partial M1 receptors agonist (EC50=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine is also a δ-opioid agonist[1][2].

HY-17387S1

(-)-Huperzine A-d4 hydrochloride

(-)-Huperzine A-d₄ hydrochloride is deuterated labeled (-)-Huperzine A (HY-17387). (-)-Huperzine A (Huperzine A) is an alkaloid isolated from Huperzia serrata, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC₅₀ of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

N-methyl-d-aspartate (NMDA)

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products